# Phase 1 Triple Negative Breast Neoplasms trials: 58 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 58 trials in phase 1 for Triple Negative Breast Neoplasms that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Triple Negative Breast Neoplasms trials: 58 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/triple-negative-breast-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 58
- Recruiting or not yet: 58
- Read on: November 19, 2026

## Trials

The 25 newest of 58, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 26, 2026 | NCT07894874 | A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors. | InventisBio Yiqi Beijing Limited | Phase 1 | Not yet recruiting | Solid Tumor (Phase I), Ovarian Cancer, NSCLC (Advanced Non-small Cell Lung Cancer), TNBC - Triple-Negative Breast Cancer | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894874) |
| September 3, 2026 | NCT07801508 | A Study of \[68Ga\]Ga-DWJ155 in Adult Patients With Solid Tumors | Novartis Pharmaceuticals | Phase 1 | Recruiting | Advanced Gastroesophageal Adenocarcinoma, Advanced Breast Cancer, Triple-negative Breast Cancer, Advanced Non-small... | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801508) |
| July 15, 2026 | NCT07705334 | A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors | SHY Therapeutics | Phase 1 | Recruiting | Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer, Gastric... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705334) |
| June 17, 2026 | NCT07652242 | Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer | Immunomic Therapeutics, Inc. | Phase 1 | Recruiting | Triple Negative Breast Cancer (TNBC) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07652242) |
| June 12, 2026 | NCT07646106 | THE-0504 in Patients With Solid Tumors | Thena Biotech S.r.l. | Phase 1 | Recruiting | Small Cell Lung Cancer (SCLC), Colorectal Carcinoma (CRC), Gastric Cancer (GC), Triple -Negative Breast Cancer... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07646106) |
| June 5, 2026 | NCT07630961 | Phase I Study of JFI447 \[68Ga\]Ga-DFC413 and Comparison to FFG233 \[68Ga\]Ga-NNS309 in Patients With Solid Tumors | Novartis Pharmaceuticals | Phase 1 | Recruiting | Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), HR+/HER2- Ductal Breast Cancer... | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07630961) |
| June 3, 2026 | NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | Huahui Health | Phase 1 | Recruiting | Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Head and Neck Squamous Cell... | 299 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623369) |
| April 22, 2026 | NCT07545122 | A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative... | Context Therapeutics Inc. | Phase 1 | Recruiting | Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Urothelial Cancer | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07545122) |
| April 8, 2026 | NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 | Recruiting | Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07517198) |
| March 31, 2026 | NCT07503808 | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types | IDEAYA Biosciences | Phase 1 | Recruiting | Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07503808) |
| February 20, 2026 | NCT07423117 | A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy | IntoCell, Inc | Phase 1 | Recruiting | Metastatic Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Metastatic... | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07423117) |
| January 14, 2026 | NCT07341867 | Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype | Sponsor not shown (see the record) | Phase 1 | Recruiting | Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation, Duffy Blood... | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07341867) |
| January 6, 2026 | NCT07318805 | A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors | Pfizer | Phase 1 | Recruiting | Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma... | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07318805) |
| December 31, 2025 | NCT07311993 | Phase 1 Study of CLR 125 in Triple Negative Breast Cancer | Cellectar Biosciences, Inc. | Phase 1 | Recruiting | Breast Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07311993) |
| December 23, 2025 | NCT07300475 | Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients | Washington University School of Medicine | Phase 1 | Not yet recruiting | Triple Negative Breast Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07300475) |
| December 22, 2025 | NCT07297667 | GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours | Canadian Cancer Trials Group | Phase 1 | Recruiting | Alveolar Soft Part Sarcoma, Renal Cell Carcinoma, Triple Negative Breast Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07297667) |
| December 9, 2025 | NCT07272642 | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. | Radiopharm Theranostics, Ltd | Phase 1 | Not yet recruiting | Imaging, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Triple Negative Breast... | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07272642) |
| December 3, 2025 | NCT07261631 | Phase I Study of \[177Lu\]Lu-DFC413 in Patients With Solid Tumors | Novartis Pharmaceuticals | Phase 1 | Recruiting | Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple... | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07261631) |
| November 14, 2025 | NCT07229313 | A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors | Kivu Bioscience Inc. | Phase 1 | Recruiting | Advance Solid Tumors | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07229313) |
| September 24, 2025 | NCT07190469 | PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer | ProteinQure Inc. | Phase 1 | Recruiting | Triple Negative Breast Cancer (TNBC), Advanced Solid Tumors Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07190469) |
| September 19, 2025 | NCT07182149 | A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors | Normunity AccelCo, Inc. | Phase 1 | Recruiting | HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Ovarian Cancer, NSCLC, Cervical... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07182149) |
| September 17, 2025 | NCT07178171 | A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC | Xijing Hospital | Phase 1 | Recruiting | TNBC, Triple Negative Breast Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07178171) |
| August 22, 2025 | NCT07137416 | Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal... | National Cancer Institute (NCI) | Phase 1 | Recruiting | Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07137416) |
| June 19, 2025 | NCT07029399 | A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors | NiKang Therapeutics, Inc. | Phase 1 | Recruiting | HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer | 361 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07029399) |
| June 13, 2025 | NCT07020117 | A Study of \[225Ac\]Ac-AKY-1189 in Patients With Solid Tumors | Aktis Oncology, Inc. | Phase 1 | Recruiting | Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07020117) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 4 |
| National Cancer Institute (NCI) | 3 |
| NiKang Therapeutics, Inc. | 2 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 2 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 2 |
| Radiopharm Theranostics, Ltd | 1 |
| IntoCell, Inc | 1 |
| Immunomic Therapeutics, Inc. | 1 |
| Nurix Therapeutics, Inc. | 1 |
| University of Southern California | 1 |
| IDEAYA Biosciences | 1 |
| InventisBio Yiqi Beijing Limited | 1 |
| Zumutor Biologics Inc. | 1 |
| [Exelixis](https://specstream.ai/data/clinical-trials/company/exelixis) | 1 |
| H. Lee Moffitt Cancer Center and Research Institute | 1 |
| Mabpro, a.s. | 1 |
| Xijing Hospital | 1 |
| Memgen, Inc. | 1 |
| UNC Lineberger Comprehensive Cancer Center | 1 |
| [Mabwell (Shanghai) Bioscience Co., Ltd.](https://specstream.ai/data/clinical-trials/company/mabwell-shanghai-bioscience-co-ltd) | 1 |
| Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 1 |
| ProteinQure Inc. | 1 |
| Hefei TG ImmunoPharma Co., Ltd. | 1 |
| OncoTherapy Science, Inc. | 1 |
| Thena Biotech S.r.l. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 43 |
| Australia | 10 |
| Spain | 9 |
| Japan | 8 |
| South Korea | 7 |
| France | 7 |
| Canada | 6 |
| Italy | 6 |
| United Kingdom | 5 |
| China | 4 |
| Germany | 4 |
| Israel | 4 |
| Belgium | 2 |
| Netherlands | 2 |
| Denmark | 2 |
| Taiwan | 2 |
| Georgia | 1 |
| Colombia | 1 |
| Switzerland | 1 |
| Singapore | 1 |
| Puerto Rico | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Fire protection companies in the United States](https://specstream.ai/data/businesses/fire-protection-companies/united-states)
- [Builders in the United States](https://specstream.ai/data/businesses/builders/united-states)
- [Truck parts suppliers in the United States](https://specstream.ai/data/businesses/truck-parts-suppliers/united-states)
- [Pediatric surgery practices in the United States](https://specstream.ai/data/businesses/pediatric-surgery-practices/united-states)
- [Hot dog restaurants in the United States](https://specstream.ai/data/businesses/hot-dog-restaurants/united-states)
- [Cosmetic dentistry practices in the United States](https://specstream.ai/data/businesses/cosmetic-dentistry-practices/united-states)
